Pfizer starts construction on plant in Saudi Arabia; Lilly's Cymbalta tops DTC list;

@FiercePharma: Merck's Tredaptive fiasco blamed on adverse reactions to niacin. Article | Follow @FiercePharma

@EricPFierce: Must be some folks sorry Mylan got Agila and they didin't. Hikma says it is getting interest in its injectables biz. Story | Follow @EricPFierce

> Pfizer ($PFE) has started construction on its first manufacturing plant in Saudi Arabia. Story

> Questions arise over whether Roche ($RHHBY) will hit a wall with the price of its new breast cancer treatment Kadcyla. Story

> Eli Lilly's ($LLY) antidepressant Cymbalta still gets the most love in the DTC advertising race. Story

> Amarin ($AMRN) reported its earnings, saying that after a debt offering it has $260.2 million on hand. Release

> Merck ($MRK) CEO Kenneth C. Frazier says big risks are are essential to the company's future. Story

> There is renewed interest in orphan drugs now that incentives make their payouts larger. Story

Biotech News

 @FierceBiotech: From FierceBiotechIT.com : GSK jumps new IT hurdles in 'real-world' test of blockbuster hopeful. Editor's Corner | Follow @FierceBiotech

@JohnCFierce: Lundbeck gets EU nod for new drug to fight alcohol addiction--$300M tops; no U.S. plans. Story | Follow @JohnCFierce

@RyanMFierce: Alere grabbed some Gates Foundation funding for Tuberculosis and HIV testing products. Release | Follow @RyanMFierce

> As sequestration dawns, FDA supporters scramble to ease woes on drug reviews. Report

> Facebook, Google geeks 'hack' into cancer research problem with mobile game. More

> FDA pins approval on once-monthly version of blockbuster Abilify. Article

Medical Device News

 @FierceMedDev: Boston Scientific posts positive Watchman data. Item | Follow @FierceMedDev

 @MarkHFierce: Fledgling Dx company GeneCentric is raising money to support a lung cancer Dx commercial launch. More | Follow @MarkHFierce

 @DamianFierce: More worry for Intuitive Surgical as the FDA gets involved in the scrutiny of da Vinci robots. Story | Follow @DamianFierce

> Wright finalizes $190M-plus buy of BioMimetic. Story

> AtriCure 2012 losses, revenue grew as market push unfolded. Article

> Alere snags up to $42.2M from Gates Foundation for TB Dx. News

And Finally... Boehringer Ingelheim has picked República as its "cross-cultural advertising agency of record." Item

Suggested Articles

That didn’t take long. Sanofi CEO Paul Hudson has only been at the reins for a couple months, but on Tuesday, he unveiled a major shakeup.  

New "gold standard" data could further increase doctors' confidence in multiple myeloma med Darzalex, Johnson & Johnson says.

Could Monday's cancer buyout be a hint about what Sanofi CEO Paul Hudson will unveil at Tuesday's investor confab? Analysts think so.